Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Insights, Forecast to 2029

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Third Generation EGFR-TKI Targeted Therapy Drugs Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
  • 1.2.2 Injection
  • 1.2.3 Tablet
  • 1.2.4 Otherss
• 1.3 Market by Application
  • 1.3.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
  • 1.3.2 Lung Cancer Treatment
  • 1.3.3 Clinical Research
  • 1.3.4 Otherss
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Estimates and Forecasts 2018-2029
• 2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region
  • 2.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region: 2018 VS 2022 VS 2029
  • 2.2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2018-2023)
  • 2.2.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2024-2029)
  • 2.2.4 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region (2018-2029)
• 2.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Estimates and Forecasts 2018-2029
• 2.4 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region
  • 2.4.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region: 2018 VS 2022 VS 2029
  • 2.4.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2018-2023)
  • 2.4.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2024-2029)
  • 2.4.4 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Region (2018-2029)
• 2.5 US & Canada
• 2.6 Europe
• 2.7 China
• 2.8 Asia (excluding China)
• 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

• 3.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Manufacturers
  • 3.1.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Manufacturers (2018-2023)
  • 3.1.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Manufacturers (2018-2023)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs in 2022
• 3.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Manufacturers
  • 3.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Manufacturers (2018-2023)
  • 3.2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Manufacturers (2018-2023)
  • 3.2.3 Global Top 10 and Top 5 Companies by Third Generation EGFR-TKI Targeted Therapy Drugs Revenue in 2022
• 3.3 Global Key Players of Third Generation EGFR-TKI Targeted Therapy Drugs, Industry Ranking, 2021 VS 2022 VS 2023
• 3.4 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Price by Manufacturers
• 3.5 Analysis of Competitive Landscape
  • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.5.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.6 Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Manufacturing Base Distribution and Headquarters
• 3.7 Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Product Offered and Application
• 3.8 Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Date of Enter into This Industry
• 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type
  • 4.1.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Historical Sales by Type (2018-2023)
  • 4.1.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Forecasted Sales by Type (2024-2029)
  • 4.1.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
• 4.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type
  • 4.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Historical Revenue by Type (2018-2023)
  • 4.2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Forecasted Revenue by Type (2024-2029)
  • 4.2.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
• 4.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price by Type
  • 4.3.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price by Type (2018-2023)
  • 4.3.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price Forecast by Type (2024-2029)

5 Market Size by Application

• 5.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application
  • 5.1.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Historical Sales by Application (2018-2023)
  • 5.1.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Forecasted Sales by Application (2024-2029)
  • 5.1.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
• 5.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application
  • 5.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Historical Revenue by Application (2018-2023)
  • 5.2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Forecasted Revenue by Application (2024-2029)
  • 5.2.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
• 5.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price by Application
  • 5.3.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price by Application (2018-2023)
  • 5.3.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price Forecast by Application (2024-2029)

6 US & Canada

• 6.1 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Type
  • 6.1.1 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2029)
  • 6.1.2 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2029)
• 6.2 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
  • 6.2.1 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
  • 6.2.2 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)
• 6.3 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Country
  • 6.3.1 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country: 2018 VS 2022 VS 2029
  • 6.3.2 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2029)
  • 6.3.3 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2029)
  • 6.3.4 US
  • 6.3.5 Canada

7 Europe

• 7.1 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Type
  • 7.1.1 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2029)
  • 7.1.2 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2029)
• 7.2 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
  • 7.2.1 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
  • 7.2.2 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)
• 7.3 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Country
  • 7.3.1 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country: 2018 VS 2022 VS 2029
  • 7.3.2 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2029)
  • 7.3.3 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2029)
  • 7.3.4 Germany
  • 7.3.5 France
  • 7.3.6 U.K.
  • 7.3.7 Italy
  • 7.3.8 Russia

8 China

• 8.1 China Third Generation EGFR-TKI Targeted Therapy Drugs Market Size
  • 8.1.1 China Third Generation EGFR-TKI Targeted Therapy Drugs Sales (2018-2029)
  • 8.1.2 China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029)
• 8.2 China Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
  • 8.2.1 China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
  • 8.2.2 China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)

9 Asia (excluding China)

• 9.1 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Type
  • 9.1.1 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2029)
  • 9.1.2 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2029)
• 9.2 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
  • 9.2.1 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
  • 9.2.2 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)
• 9.3 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region
  • 9.3.1 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region: 2018 VS 2022 VS 2029
  • 9.3.2 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2018-2029)
  • 9.3.3 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2018-2029)
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 China Taiwan
  • 9.3.7 Southeast Asia
  • 9.3.8 India

10 Middle East, Africa and Latin America

• 10.1 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Type
  • 10.1.1 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2029)
  • 10.1.2 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2029)
• 10.2 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
  • 10.2.1 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
  • 10.2.2 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)
• 10.3 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country
  • 10.3.1 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country: 2018 VS 2022 VS 2029
  • 10.3.2 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2029)
  • 10.3.3 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2029)
  • 10.3.4 Brazil
  • 10.3.5 Mexico
  • 10.3.6 Turkey
  • 10.3.7 Israel
  • 10.3.8 GCC Countries

11 Company Profiles

• 11.1 AstraZeneca
  • 11.1.1 AstraZeneca Company Information
  • 11.1.2 AstraZeneca Overview
  • 11.1.3 AstraZeneca Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.1.4 AstraZeneca Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 AstraZeneca Recent Developments
• 11.2 Hansoh Pharmaceuticak
  • 11.2.1 Hansoh Pharmaceuticak Company Information
  • 11.2.2 Hansoh Pharmaceuticak Overview
  • 11.2.3 Hansoh Pharmaceuticak Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.2.4 Hansoh Pharmaceuticak Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 Hansoh Pharmaceuticak Recent Developments
• 11.3 Aisen Pharmaceutical
  • 11.3.1 Aisen Pharmaceutical Company Information
  • 11.3.2 Aisen Pharmaceutical Overview
  • 11.3.3 Aisen Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.3.4 Aisen Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 Aisen Pharmaceutical Recent Developments
• 11.4 Nanjing Sanhome Pharmaceutical Co.Ltd.
  • 11.4.1 Nanjing Sanhome Pharmaceutical Co.Ltd. Company Information
  • 11.4.2 Nanjing Sanhome Pharmaceutical Co.Ltd. Overview
  • 11.4.3 Nanjing Sanhome Pharmaceutical Co.Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.4.4 Nanjing Sanhome Pharmaceutical Co.Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 Nanjing Sanhome Pharmaceutical Co.Ltd. Recent Developments
• 11.5 Shanghai Allist Pharmaceuticals Co., Ltd.
  • 11.5.1 Shanghai Allist Pharmaceuticals Co., Ltd. Company Information
  • 11.5.2 Shanghai Allist Pharmaceuticals Co., Ltd. Overview
  • 11.5.3 Shanghai Allist Pharmaceuticals Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.5.4 Shanghai Allist Pharmaceuticals Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 Shanghai Allist Pharmaceuticals Co., Ltd. Recent Developments
• 11.6 Jiangsu Aosaikang Pharmaceutical
  • 11.6.1 Jiangsu Aosaikang Pharmaceutical Company Information
  • 11.6.2 Jiangsu Aosaikang Pharmaceutical Overview
  • 11.6.3 Jiangsu Aosaikang Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.6.4 Jiangsu Aosaikang Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
• 11.7 Suzhou NeuPharma Co., Ltd.
  • 11.7.1 Suzhou NeuPharma Co., Ltd. Company Information
  • 11.7.2 Suzhou NeuPharma Co., Ltd. Overview
  • 11.7.3 Suzhou NeuPharma Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.7.4 Suzhou NeuPharma Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 Suzhou NeuPharma Co., Ltd. Recent Developments
• 11.8 InventisBio Co., Ltd.
  • 11.8.1 InventisBio Co., Ltd. Company Information
  • 11.8.2 InventisBio Co., Ltd. Overview
  • 11.8.3 InventisBio Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.8.4 InventisBio Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.8.5 InventisBio Co., Ltd. Recent Developments
• 11.9 Betta Pharmaceuticals Co.Ltd
  • 11.9.1 Betta Pharmaceuticals Co.Ltd Company Information
  • 11.9.2 Betta Pharmaceuticals Co.Ltd Overview
  • 11.9.3 Betta Pharmaceuticals Co.Ltd Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.9.4 Betta Pharmaceuticals Co.Ltd Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.9.5 Betta Pharmaceuticals Co.Ltd Recent Developments
• 11.10 Jiangsu Maidu Drug Research and Development Co., Ltd.
  • 11.10.1 Jiangsu Maidu Drug Research and Development Co., Ltd. Company Information
  • 11.10.2 Jiangsu Maidu Drug Research and Development Co., Ltd. Overview
  • 11.10.3 Jiangsu Maidu Drug Research and Development Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.10.4 Jiangsu Maidu Drug Research and Development Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.10.5 Jiangsu Maidu Drug Research and Development Co., Ltd. Recent Developments
• 11.11 Shanghai Saiyuan Biotechnology Co., Ltd.
  • 11.11.1 Shanghai Saiyuan Biotechnology Co., Ltd. Company Information
  • 11.11.2 Shanghai Saiyuan Biotechnology Co., Ltd. Overview
  • 11.11.3 Shanghai Saiyuan Biotechnology Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.11.4 Shanghai Saiyuan Biotechnology Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.11.5 Shanghai Saiyuan Biotechnology Co., Ltd. Recent Developments
• 11.12 EpimAb
  • 11.12.1 EpimAb Company Information
  • 11.12.2 EpimAb Overview
  • 11.12.3 EpimAb Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.12.4 EpimAb Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.12.5 EpimAb Recent Developments
• 11.13 Stellar Infinity Company Ltd.
  • 11.13.1 Stellar Infinity Company Ltd. Company Information
  • 11.13.2 Stellar Infinity Company Ltd. Overview
  • 11.13.3 Stellar Infinity Company Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.13.4 Stellar Infinity Company Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.13.5 Stellar Infinity Company Ltd. Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 Third Generation EGFR-TKI Targeted Therapy Drugs Industry Chain Analysis
• 12.2 Third Generation EGFR-TKI Targeted Therapy Drugs Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Third Generation EGFR-TKI Targeted Therapy Drugs Production Mode & Process
• 12.4 Third Generation EGFR-TKI Targeted Therapy Drugs Sales and Marketing
  • 12.4.1 Third Generation EGFR-TKI Targeted Therapy Drugs Sales Channels
  • 12.4.2 Third Generation EGFR-TKI Targeted Therapy Drugs Distributors
• 12.5 Third Generation EGFR-TKI Targeted Therapy Drugs Customers

13 Market Dynamics

• 13.1 Third Generation EGFR-TKI Targeted Therapy Drugs Industry Trends
• 13.2 Third Generation EGFR-TKI Targeted Therapy Drugs Market Drivers
• 13.3 Third Generation EGFR-TKI Targeted Therapy Drugs Market Challenges
• 13.4 Third Generation EGFR-TKI Targeted Therapy Drugs Market Restraints

14 Key Findings in The Global Third Generation EGFR-TKI Targeted Therapy Drugs Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details
• 15.3 Disclaimer

List of Tables

• Table 1. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Table 2. Major Manufacturers of Injection
• Table 3. Major Manufacturers of Tablet
• Table 4. Major Manufacturers of Otherss
• Table 5. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Table 6. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 7. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2018-2023) & (US$ Million)
• Table 8. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2024-2029) & (US$ Million)
• Table 9. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region (2018-2023)
• Table 10. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region (2024-2029)
• Table 11. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 12. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2018-2023) & (K Units)
• Table 13. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2024-2029) & (K Units)
• Table 14. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Region (2018-2023)
• Table 15. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Region (2024-2029)
• Table 16. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Manufacturers (2018-2023) & (K Units)
• Table 17. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Manufacturers (2018-2023)
• Table 18. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
• Table 19. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Manufacturers (2018-2023)
• Table 20. Global Key Players of Third Generation EGFR-TKI Targeted Therapy Drugs, Industry Ranking, 2021 VS 2022 VS 2023
• Table 21. Third Generation EGFR-TKI Targeted Therapy Drugs Price by Manufacturers 2018-2023 (US$/Unit)
• Table 22. Global Third Generation EGFR-TKI Targeted Therapy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
• Table 23. Global Third Generation EGFR-TKI Targeted Therapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Third Generation EGFR-TKI Targeted Therapy Drugs as of 2022)
• Table 24. Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Manufacturing Base Distribution and Headquarters
• Table 25. Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Product Offered and Application
• Table 26. Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Date of Enter into This Industry
• Table 27. Mergers & Acquisitions, Expansion Plans
• Table 28. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
• Table 29. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
• Table 30. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Type (2018-2023)
• Table 31. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Type (2024-2029)
• Table 32. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 33. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 34. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Type (2018-2023)
• Table 35. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Type (2024-2029)
• Table 36. Third Generation EGFR-TKI Targeted Therapy Drugs Price by Type (2018-2023) & (US$/Unit)
• Table 37. Global Third Generation EGFR-TKI Targeted Therapy Drugs Price Forecast by Type (2024-2029) & (US$/Unit)
• Table 38. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
• Table 39. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
• Table 40. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Application (2018-2023)
• Table 41. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Application (2024-2029)
• Table 42. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 43. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 44. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Application (2018-2023)
• Table 45. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Application (2024-2029)
• Table 46. Third Generation EGFR-TKI Targeted Therapy Drugs Price by Application (2018-2023) & (US$/Unit)
• Table 47. Global Third Generation EGFR-TKI Targeted Therapy Drugs Price Forecast by Application (2024-2029) & (US$/Unit)
• Table 48. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
• Table 49. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
• Table 50. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 51. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 52. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
• Table 53. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
• Table 54. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 55. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 56. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 57. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2023) & (US$ Million)
• Table 58. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2024-2029) & (US$ Million)
• Table 59. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2023) & (K Units)
• Table 60. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2024-2029) & (K Units)
• Table 61. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
• Table 62. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
• Table 63. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 64. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 65. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
• Table 66. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
• Table 67. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 68. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 69. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 70. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2023) & (US$ Million)
• Table 71. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2024-2029) & (US$ Million)
• Table 72. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2023) & (K Units)
• Table 73. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2024-2029) & (K Units)
• Table 74. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
• Table 75. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
• Table 76. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 77. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 78. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
• Table 79. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
• Table 80. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 81. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 82. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
• Table 83. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
• Table 84. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 85. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 86. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
• Table 87. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
• Table 88. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 89. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 90. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 91. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2018-2023) & (US$ Million)
• Table 92. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2024-2029) & (US$ Million)
• Table 93. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2018-2023) & (K Units)
• Table 94. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2024-2029) & (K Units)
• Table 95. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
• Table 96. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
• Table 97. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 98. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 99. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
• Table 100. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
• Table 101. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 102. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 103. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 104. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2023) & (US$ Million)
• Table 105. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2024-2029) & (US$ Million)
• Table 106. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2023) & (K Units)
• Table 107. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2024-2029) & (K Units)
• Table 108. AstraZeneca Company Information
• Table 109. AstraZeneca Description and Major Businesses
• Table 110. AstraZeneca Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 111. AstraZeneca Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 112. AstraZeneca Recent Developments
• Table 113. Hansoh Pharmaceuticak Company Information
• Table 114. Hansoh Pharmaceuticak Description and Major Businesses
• Table 115. Hansoh Pharmaceuticak Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 116. Hansoh Pharmaceuticak Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 117. Hansoh Pharmaceuticak Recent Developments
• Table 118. Aisen Pharmaceutical Company Information
• Table 119. Aisen Pharmaceutical Description and Major Businesses
• Table 120. Aisen Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 121. Aisen Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 122. Aisen Pharmaceutical Recent Developments
• Table 123. Nanjing Sanhome Pharmaceutical Co.Ltd. Company Information
• Table 124. Nanjing Sanhome Pharmaceutical Co.Ltd. Description and Major Businesses
• Table 125. Nanjing Sanhome Pharmaceutical Co.Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 126. Nanjing Sanhome Pharmaceutical Co.Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 127. Nanjing Sanhome Pharmaceutical Co.Ltd. Recent Developments
• Table 128. Shanghai Allist Pharmaceuticals Co., Ltd. Company Information
• Table 129. Shanghai Allist Pharmaceuticals Co., Ltd. Description and Major Businesses
• Table 130. Shanghai Allist Pharmaceuticals Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 131. Shanghai Allist Pharmaceuticals Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 132. Shanghai Allist Pharmaceuticals Co., Ltd. Recent Developments
• Table 133. Jiangsu Aosaikang Pharmaceutical Company Information
• Table 134. Jiangsu Aosaikang Pharmaceutical Description and Major Businesses
• Table 135. Jiangsu Aosaikang Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 136. Jiangsu Aosaikang Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 137. Jiangsu Aosaikang Pharmaceutical Recent Developments
• Table 138. Suzhou NeuPharma Co., Ltd. Company Information
• Table 139. Suzhou NeuPharma Co., Ltd. Description and Major Businesses
• Table 140. Suzhou NeuPharma Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 141. Suzhou NeuPharma Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 142. Suzhou NeuPharma Co., Ltd. Recent Developments
• Table 143. InventisBio Co., Ltd. Company Information
• Table 144. InventisBio Co., Ltd. Description and Major Businesses
• Table 145. InventisBio Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 146. InventisBio Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 147. InventisBio Co., Ltd. Recent Developments
• Table 148. Betta Pharmaceuticals Co.Ltd Company Information
• Table 149. Betta Pharmaceuticals Co.Ltd Description and Major Businesses
• Table 150. Betta Pharmaceuticals Co.Ltd Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 151. Betta Pharmaceuticals Co.Ltd Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 152. Betta Pharmaceuticals Co.Ltd Recent Developments
• Table 153. Jiangsu Maidu Drug Research and Development Co., Ltd. Company Information
• Table 154. Jiangsu Maidu Drug Research and Development Co., Ltd. Description and Major Businesses
• Table 155. Jiangsu Maidu Drug Research and Development Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 156. Jiangsu Maidu Drug Research and Development Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 157. Jiangsu Maidu Drug Research and Development Co., Ltd. Recent Developments
• Table 158. Shanghai Saiyuan Biotechnology Co., Ltd. Company Information
• Table 159. Shanghai Saiyuan Biotechnology Co., Ltd. Description and Major Businesses
• Table 160. Shanghai Saiyuan Biotechnology Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 161. Shanghai Saiyuan Biotechnology Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 162. Shanghai Saiyuan Biotechnology Co., Ltd. Recent Developments
• Table 163. EpimAb Company Information
• Table 164. EpimAb Description and Major Businesses
• Table 165. EpimAb Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 166. EpimAb Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 167. EpimAb Recent Developments
• Table 168. Stellar Infinity Company Ltd. Company Information
• Table 169. Stellar Infinity Company Ltd. Description and Major Businesses
• Table 170. Stellar Infinity Company Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 171. Stellar Infinity Company Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 172. Stellar Infinity Company Ltd. Recent Developments
• Table 173. Key Raw Materials Lists
• Table 174. Raw Materials Key Suppliers Lists
• Table 175. Third Generation EGFR-TKI Targeted Therapy Drugs Distributors List
• Table 176. Third Generation EGFR-TKI Targeted Therapy Drugs Customers List
• Table 177. Third Generation EGFR-TKI Targeted Therapy Drugs Market Trends
• Table 178. Third Generation EGFR-TKI Targeted Therapy Drugs Market Drivers
• Table 179. Third Generation EGFR-TKI Targeted Therapy Drugs Market Challenges
• Table 180. Third Generation EGFR-TKI Targeted Therapy Drugs Market Restraints
• Table 181. Research Programs/Design for This Report
• Table 182. Key Data Information from Secondary Sources
• Table 183. Key Data Information from Primary Sources

List of Figures

• Figure 1. Third Generation EGFR-TKI Targeted Therapy Drugs Product Picture
• Figure 2. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 3. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Share by Type in 2022 & 2029
• Figure 4. Injection Product Picture
• Figure 5. Tablet Product Picture
• Figure 6. Otherss Product Picture
• Figure 7. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 8. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Share by Application in 2022 & 2029
• Figure 9. Lung Cancer Treatment
• Figure 10. Clinical Research
• Figure 11. Otherss
• Figure 12. Third Generation EGFR-TKI Targeted Therapy Drugs Report Years Considered
• Figure 13. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
• Figure 14. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue 2018-2029 (US$ Million)
• Figure 15. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
• Figure 16. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region (2018-2029)
• Figure 17. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales 2018-2029 ((K Units)
• Figure 18. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Region (2018-2029)
• Figure 19. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
• Figure 20. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 21. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
• Figure 22. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 23. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
• Figure 24. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 25. Asia (excluding China) Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
• Figure 26. Asia (excluding China) Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 27. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
• Figure 28. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 29. The Third Generation EGFR-TKI Targeted Therapy Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
• Figure 30. The Top 5 and 10 Largest Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs in the World: Market Share by Third Generation EGFR-TKI Targeted Therapy Drugs Revenue in 2022
• Figure 31. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
• Figure 32. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
• Figure 33. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
• Figure 34. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
• Figure 35. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
• Figure 36. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
• Figure 37. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
• Figure 38. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
• Figure 39. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
• Figure 40. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Country (2018-2029)
• Figure 41. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Country (2018-2029)
• Figure 42. U.S. Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 43. Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 44. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
• Figure 45. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
• Figure 46. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
• Figure 47. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
• Figure 48. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Country (2018-2029)
• Figure 49. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Country (2018-2029)
• Figure 50. Germany Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 51. France Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 52. U.K. Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 53. Italy Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 54. Russia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 55. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
• Figure 56. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
• Figure 57. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
• Figure 58. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
• Figure 59. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
• Figure 60. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
• Figure 61. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
• Figure 62. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
• Figure 63. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Region (2018-2029)
• Figure 64. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Region (2018-2029)
• Figure 65. Japan Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 66. South Korea Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 67. China Taiwan Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 68. Southeast Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 69. India Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 70. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
• Figure 71. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
• Figure 72. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
• Figure 73. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
• Figure 74. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Country (2018-2029)
• Figure 75. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Country (2018-2029)
• Figure 76. Brazil Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 77. Mexico Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 78. Turkey Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 79. Israel Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 80. GCC Countries Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
• Figure 81. Third Generation EGFR-TKI Targeted Therapy Drugs Value Chain
• Figure 82. Third Generation EGFR-TKI Targeted Therapy Drugs Production Process
• Figure 83. Channels of Distribution
• Figure 84. Distributors Profiles
• Figure 85. Bottom-up and Top-down Approaches for This Report
• Figure 86. Data Triangulation
• Figure 87. Key Executives Interviewed